Upgrade to SI Premium - Free Trial

Truist Securities on Vanda Pharmaceuticals (VNDA): EMA news is just 'noise'

March 27, 2026 11:24 AM
Truist Securities analyst Les Sulewski reiterated a Buy rating and $18.00 price target on Vanda Pharmaceuticals (NASDAQ: VNDA)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments